Table 1.

Major safety outcomes for TNFα inhibitors, selective immunosuppressants, and interleukin inhibitors, as reported on the summaries of product characteristics and risk management plans

RMP risk management plan, SmPC summary of product characteristics, TNF tumor necrosis factor

^aSmPC: paragraph 4.4, Special warnings and precautions for use

^bRMP: Important identified risk (red shading)

^cRMP: Important potential risk (blue shading)